A Phase 2/3 interventional study of NVA237 (glycopyrronium bromide) and Placebo in Asthma, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.
Among the 10 studies testing glycopyrrolate in Asthma, this one is the 3rd largest by enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 6th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Bulgaria, Colombia, Guatemala and 5 more countries
Ages 6–11
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 4 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 10 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
105 studies in Asthma by Novartis: 3 open now, 5 under way, 2 of them phase 3. Of 93 finished, 61 (66%) have results posted.
Among the 105 studies in Asthma by Novartis, this one is the 39th largest by enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2017, is one of 2 in phase 2/3, and was the 82nd registered.
Novartis’s Asthma studies by the year they started, since 2001.
1 of the studies testing glycopyrrolate in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05222529Novartis PharmaceuticalsPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing glycopyrrolate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 105 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
This study uses a randomized, double-blind, placebo controlled, 3-period cross-over clinical trial design. During a screening epoch patient eligibility will be assessed. The screening epoch will be followed by a 21-day Run-in epoch during which patients will continue their inhaled corticosteroids use but be withdrawn from LABA-treatment and switched to short-acting bronchodilator-rescue medication. After the Run-in period patients will be randomized to one of the 6 treatment sequences and enter the first 7-day study treatment period. Treatment period one is followed by a 10 to 14 days washout period after which patients begin the second 7-day treatment period which is then followed by a second 10 to 14 days washout period followed by the third 7-day treatment period. At the end of each treatment period spirometry will be performed to assess the primary endpoint in terms of trough FEV1. The study population will consist of approximately 144 patients with asthma who have been treated in a stable regimen of ICS/LABA for at least 4 weeks prior to screening.
Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment sequence: NVA 237 50 ug, 25 ug and placebo
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
Treatment sequence: NVA 237 50 ug, placebo and 25 ug
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
Treatment sequence: NVA237 25 ug, 50 ug and placebo
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
Treatment sequence: NVA 237 25 ug, placebo and 50 ug
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
Treatment sequence: Placebo, NVA237 50 ug and 25 ug
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
Treatment sequence: placebo, NVA237 25 ug and 50 ug
Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo
In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
In each treatment arm, patient will receive placebo
Trough FEV1 After One Week of Treatment, Point Estimate
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period. Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 15 min and 23h 45 min post dose.
Time frame: Following 1 week of treatment
FEV1 AUC (5 Min-1 h) After One Week of Treatment
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-1h)
Time frame: Following 1 week of treatment
FEV1 AUC (5 Min-4 h) After One Week of Treatment
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-4h)
Time frame: Following 1 week of treatment
FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day AUC (5 min - 23 h 45 min)
Time frame: Following 1 week of treatment
Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The peak effect following 1 week of treatment was defined as the maximum FEV1 during the first 4 hour on that day.
Time frame: Following 1 week of treatment
Trough Forced Vital Capacity (FVC) After 1 Week of Treatment
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period. Trough Forced Vital Capacity (FVC) following 7 Days. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry
Time frame: Following 1 week of treatment
Percent Change From Baseline in FEV1/FVC Ratio
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period
Time frame: Following 1 week of treatment
Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value
Time frame: Following 1 week of treatment
Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
Time frame: Following 1 week of treatment
Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs.
Time frame: Following 1 week of treatment
| Milestone | 1(NVA237 50 ug/NVA237 25 ug/Placebo) | 2(NVA237 50 ug/Placebo/NVA237 25 ug) | 3 (NVA237 25 ug/NVA237 50 ug/Placebo) | 4 (NVA237 25 ug/Placebo/NVA237 50 ug) | 5 (Placebo/NVA237 50 ug/ NVA237 25 ug) | 6 (Placebo/ NVA237 25 ug/NVA237 50 ug) |
|---|---|---|---|---|---|---|
| Started | 24 | 25 | 25 | 24 | 25 | 25 |
| Completed | 22 | 24 | 25 | 24 | 24 | 25 |
| Not completed | 2 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject/guardian decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study treatment | 0 | 0 | 0 | 0 | 1 | 0 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period. Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 15 min and 23h 45 min post dose.
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Trough FEV1 After One Week of Treatment, Point Estimate | 2.392 ± 0.0249 | 2.392 ± 0.0250 | 2.303 ± 0.0247 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-1h)
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| FEV1 AUC (5 Min-1 h) After One Week of Treatment | 2.489 ± 0.0226 | 2.492 ± 0.0228 | 2.324 ± 0.0227 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-4h)
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| FEV1 AUC (5 Min-4 h) After One Week of Treatment | 2.522 ± 0.0223 | 2.525 ± 0.0224 | 2.346 ± 0.0223 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day AUC (5 min - 23 h 45 min)
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment | 2.443 ± 0.0226 | 2.450 ± 0.0227 | 2.304 ± 0.0226 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The peak effect following 1 week of treatment was defined as the maximum FEV1 during the first 4 hour on that day.
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment | 2.621 ± 0.0228 | 2.630 ± 0.0229 | 2.457 ± 0.0228 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period. Trough Forced Vital Capacity (FVC) following 7 Days. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry
| Liters | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Trough Forced Vital Capacity (FVC) After 1 Week of Treatment | 3.509 ± 0.0268 | 3.530 ± 0.0269 | 3.472 ± 0.0267 |
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period
| Percent change | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Percent Change From Baseline in FEV1/FVC Ratio | 0.018 ± 0.0421 | 0.016 ± 0.0438 | 0.003 ± 0.0398 |
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value
| L/min | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period | 395.09 ± 2.948 | 393.87 ± 2.962 | 369.58 ± 2.958 |
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
| L/min | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment | 409.66 ± 2.928 | 408.08 ± 2.934 | 378.72 ± 2.949 |
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs.
| Puffs/day | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment | 0.98 ± 0.094 | 1.02 ± 0.094 | 1.13 ± 0.094 |
Collected over Following 1 week of treatment. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 50 ug | 0/147 (0%) | 1/147 (0.7%) | 10/147 (6.8%) |
| NVA237 25 ug | 1/146 (0.7%) | 1/146 (0.7%) | 11/146 (7.5%) |
| Placebo | 0/146 (0%) | 0/146 (0%) | 11/146 (7.5%) |
| Event | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| Completed suicidePsychiatric disorders | 0/147 | 1/146 | 0/146 |
| Patellofemoral pain syndromeMusculoskeletal and connective tissue disorders | 1/147 | 0/146 | 0/146 |
| Event | NVA237 50 ug | NVA237 25 ug | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 5/147 | 2/146 | 2/146 |
| NasopharyngitisInfections and infestations | 2/147 | 1/146 | 3/146 |
| Upper respiratory tract infectionInfections and infestations | 1/147 | 3/146 | 1/146 |
| Muscle strainInjury, poisoning and procedural complications | 1/147 | 0/146 | 2/146 |
| DizzinessNervous system disorders | 1/147 | 0/146 | 2/146 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/147 | 2/146 | 0/146 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/147 | 2/146 | 0/146 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/147 | 2/146 | 1/146 |
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 47.3 ± 11.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 75 |
| Male | 73 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 16 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 12 |
| White | 120 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2017 to primary completion in Dec 2017, 7 months.
Results were first posted in Jan 2019, 1 year after primary completion.
Of 14 phase 2/3 interventional studies under Asthma, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate